The Victor Babeș University of Medicine and Pharmacy, Timișoara (Romanian: Universitatea de Medicină și Farmacie "Victor Babeș", or UMF Timișoara) is located in Timișoara, Romania. It was named in honor of the scientist Victor Babeș.
Purpose The persistent proatlantal artery represents persistence of the embryonic first cervical intersegmental artery and creates a carotid-vertebral anastomosis. A persisting carotid duct is an exceptionally rare persistence of the dorsal aortic segment between the third and fourth aortic arches. It may be associated with segmental occlusion/stenosis of the proximal external carotid artery. Methods Archived computed tomography angiography files in a 62 year-old man were studied anatomically. Results A right-sided persisting carotid duct arising from the subclavian artery with short proximal ECA occlusion/stenosis and reconstitution of the distal ECA was found. A large type II PPA arose from the reconstituted ECA, formed a suboccipital loop giving rise to the occipital segment of the occipital artery, and established two distinct junctions with the vertebral artery: an anterior branch to the V3 segment near the posterior condylar foramen and an inferior branch to the V2 segment immediately before entry into the C1 transverse foramen. Conclusion This configuration provides imaging evidence of a true 'double-connection' of a persisting proatlantal artery, coexisting with a persisting carotid duct and proximal external carotid occlusion/stenosis, with potential implications for carotid interventions and posterior-circulation haemodynamics.
This review addresses the escalating global water crisis driven by water pollution, especially by heavy metal ions, a consequence of rapid industrialization and population growth. Due to their high toxicity, solubility, and persistence, heavy metals pose a severe threat to human health and ecosystems through bioaccumulation. The analysis highlights a strategic shift in wastewater management from simple elimination of the toxics metal ions to the recovery of metal ions with economic value. Given the increasing complexity of industrial effluents, the scientific community is intensifying its focus on evaluating the technical and financial feasibility of various treatment technologies. Significant research is being conducted to address these environmental issues, and innovative technologies are being developed to enhance the quality of water contaminated by metal ions. On the other hand, to prevent pollution, plans containing several barriers must be established, including management, economic, and technical ones. Ultimately, the reuse of treated wastewater is the only viable long-term solution for securing global drinking water supplies. A new analysis focused on the transition from traditional, inefficient, and costly wastewater treatment to advanced, resource recovery-oriented systems is essential. The current perspective shows a clear need to advance beyond synthetic laboratory studies to real-world applications while addressing operational barriers to support a circular economy based on simple disposal of the toxic metal ions to the recovery of metals with economic value (e.g., copper, gold, silver, rare metals). Also, although the field has been explored, a new review is imperative because current technologies that show high efficiency (up to 99%) in the removal of toxic metal ions (adsorption, membrane filtration, electrochemical processes) face major challenges, such as the formation of large volumes of toxic sludge, membrane fouling, and high operating costs.
Background/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide well-established cardiovascular and renal benefits in heart failure (HF), type 2 diabetes (T2DM), and chronic kidney disease (CKD). Although emerging trials suggest potential value after acute myocardial infarction (AMI), SGLT2 inhibitors currently have no formal indication for AMI, and real-world prescribing patterns in this setting remain uncharacterized. This study aimed to evaluate in-hospital and post-discharge prescribing patterns and clinical predictors of SGLT2 inhibitor initiation among AMI patients eligible for therapy based on guideline-supported indications. Methods: We conducted a retrospective cohort study including 244 consecutive AMI patients hospitalized between January 2023 and July 2024. A total of 180 (73.7%) met guideline-based eligibility criteria for SGLT2 inhibitors. Four multivariable logistic regression models were developed to identify independent predictors of SGLT2 inhibitor prescription. Results: A total of 117 patients (65%) received SGLT2 inhibitors and 63 (35%) remained untreated. Receivers were more frequently male (81% vs. 65%) and exhibited lower left ventricular ejection fraction (LVEF) (38.2 ± 6.7% vs. 42.4 ± 8.3%), larger ventricular volumes, and higher Killip class at presentation. HF patients with preserved ejection fraction (HFpEF) were markedly undertreated (25.9%) compared with mid-range (HFmrEF) (69.8%) or reduced (HFrEF) (73.7%). Across all models, HFpEF was a strong negative predictor of prescribing (OR 0.071-0.081, p < 0.001), while male sex and markers of clinical severity were associated with higher likelihood of initiation. Many untreated patients had T2DM or CKD despite guideline-based eligibility. No serious adverse events attributable to SGLT2 inhibitors were reported. Conclusions: In this real-world AMI cohort, SGLT2 inhibitors were prescribed primarily in relation to established indications for HF, T2DM, and CKD, yet their use remained highly variable in the absence of a dedicated recommendation for AMI. Significant therapeutic gaps were observed in HFpEF and high-risk cardiometabolic profiles, underscoring the need for clearer guidance and standardized pathways to support consistent initiation in eligible patients after MI.
Context/Objectives: Pectus excavatum (PE), the most common anterior chest wall deformity in children and adolescents, impacts posture and is frequently associated with axial deviations due to biomechanical alterations of the spine and the properties of the involved musculature. Methods: We assessed 35 patients with PE with a Haller index below 3.25, aged between 5 and 17 years, who completed a three months specialized physical exercise program after proper training and instruction by a specialist. All patients were assessed before starting the exercise program and at the end of the treatment. The assessment method used was myotonometry, employing the MyotonPRO device, targeting the trapezius muscle with all three fascicles and the pectoralis major muscle both on the left and the right side, measuring: frequency (Hz), stiffness (N/m), decrement, relaxation time (ms), and the ratio between relaxation time and deformation time (creep). Results: The analysis of myotonometric parameters reveals a pattern of selective adaptation, predominantly involving the left hemibody in most of the groups analyzed, without significant functional imbalances. This asymmetry may reflect either the functional predominance of the left hemibody during participants' daily activities or increased activation induced by the exercise program; however, by the end of the intervention, bilateral stability was observed in most parameters. Conclusions: A three-month physical exercise program in children and adolescents with PE results in improvements in muscle properties, particularly in the pectoralis major and middle trapezius muscles bilaterally, and contributes to the restoration of functional symmetry, thereby supporting the effectiveness of the exercise program in optimizing neuromuscular control, tissue elasticity, and scapular stability.
AS, one of the most common forms of valvular heart disease, requiring intervention in aging populations in Europe and North America, has traditionally been viewed as a passive, degenerative condition. However, growing evidence supports a paradigm shift toward recognizing AS as an active metabolic and inflammatory disorder. This narrative review synthesizes experimental, translational, and clinical evidence published between 2015 and 2025 examining metabolic mechanisms linking valvular calcification and atrial remodeling in AS and discusses their clinical relevance in the context of transcatheter aortic valve replacement (TAVR). We discussed classical pathways involving mineral metabolism and vitamin signaling, alongside emerging roles of lipid oxidation, mitochondrial dysfunction, epigenetic regulation, and gut microbiome-derived metabolites. Further, metabolomic signatures associated with disease severity and post-TAVR outcomes were reviewed, highlighting the predominantly associative nature and current limitations of these data. Although valve replacement remains the only effective therapy for advanced AS, metabolic and multi-omics insights may improve future risk stratification and mechanistic understanding. Metabolomic profiling could be integrated at multiple points in the clinical pathway for aortic stenosis and TAVR—most promisingly for pre-procedural risk stratification. The present paper focuses on an integrative framework in which valvular calcification and atrial remodeling are viewed within a broader context of metabolic dysregulation. Future research should aim to translate molecular biomarkers into real-world diagnostics and targeted interventions.
